Editas becomes latest gene editing company to turn to more common diseasesnews2025-09-02T15:26:33+00:00September 2nd, 2025|Endpoints News|
Upstream Bio’s Phase 2 win could set it up as a potential Dupixent, Tezspire competitornews2025-09-02T15:17:06+00:00September 2nd, 2025|Endpoints News|
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engagernews2025-09-02T15:10:59+00:00September 2nd, 2025|Endpoints News|
Arrowhead piques Novartis’ neuro interest with $200M upfront dealnews2025-09-02T14:59:15+00:00September 2nd, 2025|Endpoints News|
Post-Hoc Live: What it takes to build a new biotech in 2025news2025-09-02T13:58:51+00:00September 2nd, 2025|Endpoints News|
Exclusive: Neon Health raises $6M for AI to help patients access specialty drugsnews2025-09-02T13:00:49+00:00September 2nd, 2025|Endpoints News|
Ionis says ‘unprecedented’ data support Tryngolza’s label expansion in severe triglyceride diseasenews2025-09-02T11:00:26+00:00September 2nd, 2025|Endpoints News|
John Maraganore, Clive Meanwell team up again with $50M to prevent cardiovascular diseasenews2025-09-02T10:30:45+00:00September 2nd, 2025|Endpoints News|
Nvidia-backed Charm Therapeutics gets $80M to take AI-designed cancer drug to clinicnews2025-09-02T06:00:07+00:00September 2nd, 2025|Endpoints News|
#ESC25: Novartis’ Leqvio cuts lipid levels, muscle pain in high-risk cholesterol patientsnews2025-08-30T15:00:23+00:00August 30th, 2025|Endpoints News|
